Express Pharma

Vaccines in pipeline will work against the new COVID-19 variants: Dr K Raghavan

Committee of experts to soon give report on the process of identifying and prioritising patients with co-morbidities, for the purpose of vaccination: Dr VK Paul

0 284

In a major development this week, Indian SARS-CoV-2 Genomics Consortium (INSACOG) has been formed with 10 government laboratories to ascertain the current status of the new variant of SARS-CoV-2 (SARS-CoV-2 VUI 202012/01) in the country, informed a release from MoH&FW. Its function is also to establish sentinel surveillance for early detection of genomic variants with public health implication and to determine the genomic variants in the unusual events/trends.

Dr K Raghavan, Principal Scientific Adviser assured that vaccines in the pipeline in India and all over the world will work against the new variants of SARS-CoV-2. In this context, he explained that there is no evidence that current vaccines will fail to protect against COVID-19 variants reported from the UK or South Africa.

He said, “The changes in the variants are not sufficient to make the vaccines ineffective. Most of the vaccines target the spike protein, in which there are changes in the variants. But vaccines stimulate our immune system to produce a wide range of protective antibodies.”

Dr Raghavan further explained, “Changes have been observed in the ‘S’ proteins on the surface of the new variants of coronavirus. The viruses undergo changes from time-to-time. Most of these changes do not affect the virus or even the spread of infection. But, sometimes changes are such that its intensity of transmission and other properties change. Such a concern has been raised at UK and South Africa presently. This new strain of SARS-Cov-2 show 17 changes in the spike protein, out of which eight are in the part which codes for the spike protein. One such change increases affinity for ACE2 receptor, used for entry in human cells. Thus its power of transmission has increased. Another change promotes entry into susceptible cells. These changes are causing concerns. Field data has also shown the UK variant to be more transmissible. This is spreading very rapidly and taking over the frequency of all other variants. It is also reflected in the large positivity in UK. There is no evidence so far that it increases severity of the disease. But, because it increases transmission, it will affect the number of people who are affected and, therefore, the number of severely diseased people. Therefore, we must take extraordinary precautions to prevent this kind of variants from dominating a population”.

Speaking about the measures taken in India to control the transmission of this new variant in India, Dr Raghavan said, INSACOG consortium will do testing and sequencing of samples from not only international travellers, but also from across the country and from those being admitted to hospitals. In a word of caution, Dr Raghavan advised that there should not be any complacency in our behaviour, inspite of a decline in positivity and death rate. “A vaccine will be available soon and it will surely be an exit visa for the virus, but the process of rolling out the vaccine will take time. Till then follow all public health measures scrupulously”, he added.

Speaking about the new variant and mutation that occurs in viruses, Prof (Dr) Balram Bhargava, DG-ICMR said that it is important that we do not put too much immune pressure on the virus by which it will tend to mutate more. He advised judicious use of therapies for which benefits have been established and stopping use of all those therapies for which benefits have not been proven. In the context of efficacy of vaccines on the new strain, he said,” Much of the #vaccines that are the front-runners are targeting the ‘S’ protein and also the mRNA. We find that they will continue to be effective from the available data. We have to be careful about any immunity break-through that may happen during #vaccination”. DG-ICMR also said, “Much of the vaccines that are the front-runners are targeting the ‘S’ protein and also the mRNA. We find that they will continue to be effective from the available data”.

Cautioning about the new variant, Dr VK Paul, Member (Health), NITI Aayog stated, “This new variant of SARS-CoV-2 strain may have its own run. We have to be very careful. When a new virus enters, it is easy to suppress it in t